Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

Arjun V. Balar, MD
Published: Tuesday, Jul 11, 2017



Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

The treatment landscape for bladder cancer has changed dramatically over the last 5 years, according to Balar. The entire field has shifted towards immunotherapy and there are now 5 drugs approved in the second line setting and 2 drugs approved in the first line setting.

In the future, the field needs to look beyond PD-1/PD-L1 antibodies and investigate novel combinations, states Balar.
 


Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

The treatment landscape for bladder cancer has changed dramatically over the last 5 years, according to Balar. The entire field has shifted towards immunotherapy and there are now 5 drugs approved in the second line setting and 2 drugs approved in the first line setting.

In the future, the field needs to look beyond PD-1/PD-L1 antibodies and investigate novel combinations, states Balar.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x